Bayer to Invest $150 Million in New Cell Manufacturing Plant in Berkeley

Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind its competitors. “Bayer is deeply committed to bringing innovative medicines to market that provide significant patient benefit,” stated Wolfram Carius, executive vice president and Head of Bayer Pharmaceuticals Product Supply. ���This investment allows Bayer to expand our biologics development and launch capabilities, as we advance our R&D programs internally and through strategic collaborations. We are especially proud to bring this investment to Berkeley, where Bayer has been for many years, and to the greater San Francisco Bay Area, the birthplace of biotechnology and a global epicenter of drug development innovation.”